On 8 July, Fundación Mutua Madrileña presented its 23rd Medical Research Grants, endowed with 2.3 million euros, to 21 new…
Breast Cancer Group
On 24 April, members of the “El Rosa Melocotón” association visited VHIO’s facilities to present their annual fundraising donation in…
Volem Purpurina is a non-profit association dedicated to health and social causes. Within the organisation there is a section called…
Marinada is a self-help group for women affected by breast cancer. Founded in 2005, the group has maintained a strong…
Results from the multicenter, open-label, randomized phase 3 DESTINY Breast11 trial show that neoadjuvant antibody-drug conjugate trastuzumab deruxtecan improved pathological…
Final overall survival analysis from the phase 3 INAVO120 study demonstrates that first-line inavolisib in combination with standard-of care palbociclib-fulvestrant…
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
